Aging is associated with slower renal progression in patients with chronic kidney disease

Chia-Tse Yeh, Chun-Yu Lin, Ting-Yun Lin, Ching-Hsiu Peng, Yi-Chun Wang, Szu-Chun Hung

Abstract

Objectives: Chronic kidney disease (CKD) is prevalent among the elderly. However, little is known about how the clinical course of CKD vary with age. The purpose of this study was to examine the impact of aging on the risk of end-stage kidney disease (ESKD) in patients with moderate to advanced CKD. Materials and Methods: A total of 454 patients with stages 3–5 CKD were prospectively followed for a median of 5.1 years. The primary outcome was ESKD needing chronic dialysis therapy or preemptive kidney transplantation. The secondary outcome was a composite of ESKD or all-cause mortality. Results: The mean age of the patients was 65 ± 13 years. 65.4% were men, 44.9% had diabetes mellitus, and 22.7% had cardiovascular disease. Overall, 142 participants progressed to ESKD and 63 participants died. Compared with young patients (age <65 years, n = 205), elderly patients (age ≥65 years, n = 249) were associated with a significantly decreased risk of ESKD in Cox proportional hazards models adjusted for sex, smoking history, diabetes mellitus, cardiovascular disease, systolic blood pressure, estimated glomerular filtration rate, urine protein: creatinine ratio, use of renin-angiotensin-aldosterone blocker, hemoglobin, phosphate, interleukin-6, body mass index, and N-terminal pro-brain natriuretic peptide (hazard ratio [HR]: 0.66; 95% confidence interval [CI]: 0.45, 0.96; P = 0.028). The results remained statistically significant when death as a competing risk was taken into account (subdistribution HR: 0.65; 95% CI: 0.45, 0.95, P = 0.026). Notably, elderly did not predict a higher risk for the composite outcome (HR: 0.94; 95% CI: 0.67, 1.32; P = 0.723). Conclusion: Elderly confers a decreased risk of ESKD in Taiwanese patients with moderate to advanced CKD. Our findings suggest that age is an important effect modifier for CKD progression.

Keywords: Aging, Chronic kidney disease, End-stage kidney disease, Mortality

We hypothesized that the risk of ESKD among patients with stages 3–5 CKD who were not yet on dialysis would differ substantially across age groups. In the present study, we tested this hypothesis among a CKD cohort of 454 patients who received care in the Taipei Tzu Chi Hospital by comparing the relative risk of ESKD between young (age <65 years) and elderly patients (age ≥65 years).
Materials and Methods

Study participants

This was a prospective cohort study conducted in the outpatient clinics of the Taipei Tzu Chi Hospital, Taiwan. CKD patients $> 18$ years of age were assessed for eligibility for inclusion between September 2011 and March 2020. CKD was defined by two separate estimated glomerular filtration rate (eGFR) values $< 60$ mL/min per 1.73 m$^2$; calculated with the use of the four-variable Modification of Diet in Renal Disease (MDRD) formula [4], over an interval of 3 months. Exclusion criteria included active malignancies, acute infectious diseases, chronic inflammatory diseases, kidney injury due to reversible reasons, pregnancy, liver cirrhosis, or clinical conditions affecting body composition measurements such as amputees and patients with a cardiac pacemaker or metallic implants. Patients who were expected to enter dialysis treatment within 3 months were also ineligible. All patients received multidisciplinary CKD care plans including restriction of dietary salt and protein and avoidance of any nephrotoxic agent. Participants were followed up every 3 months during a routine clinical visit. The study fulfilled the Declaration of Helsinki and was approved by the Institutional Review Board (01-XD13-034 and 07-XD-074). Written informed consent was provided by each participant.

Data collection

Information on participant demographics, comorbidities, and medications was obtained at the time of study enrollment. Cardiovascular disease (CVD) included coronary artery disease defined by either coronary angiography or a history of myocardial infarction, New York Heart Association class III to IV heart failure, and cerebrovascular accident. Diabetes mellitus was defined as current or past use of insulin and/or oral antidiabetic drugs. Hypertension was defined as blood pressure $\geq 140/90$ mmHg or current use of antihypertensive medications.

All blood samples were taken from the participants after overnight fasting. Serum albumin was determined with a bromocresol purple method. Plasma levels of interleukin-6 (IL-6) (RandD Systems, Minneapolis, MN) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) (Roche Diagnostics, Indianapolis, IN) were measured using the commercially available enzyme-linked immunosorbent assay kits according to the manufacturer’s instructions. Proteinuria was quantified from a first-morning urine protein-to-creatinine ratio (UPCR) in g/g. Other laboratory measurements, including glucose, lipids, and electrolytes, were carried out according to routine laboratory methods.

Outcomes

The primary outcome was incident ESKD, defined as the need for chronic dialysis therapy or preemptive kidney transplantation. Death and loss to follow-up were considered censoring events. The secondary outcome was a composite of ESKD or death from any cause. Causes of death were confirmed by official death certificates. The follow-up time for each participant started at the first study visit and continued until July 2020.

Statistical analyses

Continuous data with or without a normal distribution were expressed as means $\pm$ standard deviations or medians and interquartile ranges (IQR) and compared using Student’s $t$-test or Mann–Whitney $U$ test, respectively. Categorical data were expressed as numbers and percentages and compared by the Chi-square test. The Cox proportional hazards models were used to determine the association between age and outcomes. Variables that were clinically relevant were considered to be adjusted in the multivariable models, and at most one variable per 10 observed events was included to avoid overfitting. Thus, Model 1 was adjusted for eGFR, and UPCR. Model 2 was additionally adjusted for sex, smoking history, diabetes mellitus, and CVD. Model 3 was additionally adjusted for use of renin-angiotensin-aldosterone blocker (RASB), systolic blood pressure, body mass index (BMI), hemoglobin, phosphate, IL-6, and NT-proBNP. Furthermore, we performed competing risk analyses according to Fine and Gray on incident ESKD, considering pre-ESKD death as a competing event [5]. Effect modification of the association between age and ESKD by 6 clinically important variables that may affect prognosis (sex, diabetes, CVD, use of RASB, BMI $< 25$ vs. $\geq 25$ kg/m$^2$), and UPCR ($< 1$ vs. $\geq 1$ g/g) was also tested by including multiplicative interaction terms in the multivariable model. A two-tailed $P < 0.05$ was considered statistically significant. Computer software Statistical Package for the Social Sciences version 20.0 (SPSS, Chicago, IL, USA) was used for all analyses.

Results

Patient characteristics

The study cohort was composed of 454 patients (157 women and 297 men; mean age 65 $\pm$ 13 years) with moderate to advanced CKD (mean eGFR 27 $\pm$ 15 mL/min per 1.73 m$^2$). Among them, 84.1% had hypertension ($n = 382$), 44.9% had diabetes mellitus ($n = 204$), and 22.7% had CVD ($n = 103$). The most common renal diagnoses in this cohort were diabetic nephropathy (44.9%) and glomerular diseases (32.4%); 22.7% of the patients had hypertensive nephrosclerosis or unknown etiology of CKD. The baseline demographic and clinical characteristics for the patient groups divided based on age $< 65$ or $\geq 65$ years are presented in Table 1. Compared with younger patients, older patients had a higher prevalence of CVD and a higher systolic blood pressure, IL-6, and NT-proBNP, but had a lower BMI and triglycerides. There were no significant differences in the prevalence of diabetes and the use of diuretics and statin between the two groups. As expected, a lower hemoglobin levels were observed in older patients. In addition, significant differences in baseline eGFR and UPCR were observed between both groups. For older patients, the mean eGFR values were 26 $\pm$ 14 mL/min per 1.73 m$^2$, and the median UPCR was 0.72 (IQR 0.30–1.98); for younger patients, the mean eGFR values was 29 $\pm$ 15 mL/min per 1.73 m$^2$, and the median UPCR was 1.06 (IQR 0.47–2.85).

Outcomes

During a median follow-up period of 5.1 years, there were 142 ESKD events (74 younger patients and 68 older patients) and 63 deaths from any cause (14 younger patients and 49
older patients). The overall causes of death were infectious in 38.1%, cardiovascular in 36.5%, malignancy in 12.7%, and others in 12.7%.

Table 2 shows the results of the multivariable Cox proportional hazard analyses for the risk of ESKD in younger and older patients. In a model adjusted for eGFR and UPCR, older patients had 27% lower risk of incident ESKD compared with younger patients (hazard ratio [HR]: 0.73; 95% confidence interval [CI]: 0.52–1.03; \( P = 0.070 \)). This risk became significantly lower after adjusting for additional demographic and clinical variables (HR: 0.66; 95% CI: 0.45–0.96; \( P = 0.028 \)). Of note, older patients were not associated with a higher risk of the composite outcome in fully adjusted models (HR: 0.94; 95% CI: 0.67–1.32; \( P = 0.723 \)). After the competing risk of pre-ESKD death was taken into account, older patients remained significantly associated with a lower risk of ESKD in fully adjusted models (subdistribution HR: 0.65, 95% CI: 0.45-0.95; \( P = 0.026 \)).

Subgroup analyses are shown in Figure 1. The lower risk of ESKD associated with aging was consistent across all clinically relevant subgroups. Notably, significant interactions were observed for men versus women, with a benefit favoring men, and for the presence versus absence of diabetes at baseline, with benefit for those with diabetes.

**Discussion**

In this prospective cohort study, we demonstrated that aging is associated with a lower risk of ESKD in patients with stage 3–5 CKD. This association was consistent after extensive adjustment of multiple confounders and accounting for competing risk of death. Our findings were compatible with the results of previous studies from other ethnicities [3,6,7], indicating that similar levels of eGFR may have very different prognostic implications between younger and older patients.

The lower incidence of ESKD among older compared with younger patients with CKD may reflect age differences in the underlying cause of low eGFR. In older patients, perhaps lower eGFR results more frequently from “normal” aging rather than from a disease process and functions more commonly

| Table 1: Baseline characteristics of the patients stratified by age | Age <65 years (n=205), n (%) | Age ≥65 years (n=249), n (%) | P |
| --- | --- | --- | --- |
| Age (years) | 53±9 | 75±7 | <0.001 |
| Sex | 130 (63.4) | 167 (67.1) | 0.415 |
| Smoking history | 52 (25.4) | 63 (25.3) | 0.987 |
| Hypertension | 166 (81.0) | 216 (86.7) | 0.094 |
| DM | 89 (43.4) | 115 (46.2) | 0.555 |
| CVD | 31 (15.1) | 72 (28.9) | <0.001 |
| CAD | 17 (8.3) | 38 (15.3) | 0.024 |
| CHF | 9 (4.4) | 33 (13.3) | 0.001 |
| Stroke | 10 (4.9) | 18 (7.2) | 0.300 |
| Loop diuretics | 34 (16.6) | 58 (23.3) | 0.077 |
| Thiazide | 31 (15.1) | 31 (12.4) | 0.409 |
| CCB | 100 (48.8) | 131 (52.6) | 0.417 |
| RASB | 138 (67.3) | 140 (56.2) | 0.016 |
| Statin | 80 (39.0) | 77 (30.9) | 0.071 |
| Body weight (kg) | 71.2±16.4 | 64.1±10.9 | <0.001 |
| Height (cm) | 162.9±8.8 | 158.8±8.2 | <0.001 |
| BMI (kg/m²) | 26.6±5.0 | 25.4±3.5 | 0.002 |
| Systolic BP (mm Hg) | 134±18 | 140±19 | 0.001 |
| Diastolic BP (mm Hg) | 82±13 | 78±13 | 0.001 |
| eGFR (mL/min/1.73 m²) | 29±15 | 26±14 | 0.020 |
| UPCR (g/g) | 1.06 (0.47-2.85) | 0.72 (0.30-1.98) | 0.008 |
| Creatinine (mg/dL) | 3.0±1.9 | 3.1±1.0 | 0.642 |
| Hemoglobin (g/dL) | 12.0±2.2 | 11.4±2.0 | 0.004 |
| Sodium (mmol/L) | 137 (135-139) | 138 (136-140) | 0.011 |
| Potassium (mmol/L) | 4.4 (4.0-4.8) | 4.4 (4.0-4.8) | 0.738 |
| Calcium (mg/dL) | 9.0 (8.7-9.3) | 8.9 (8.6-9.2) | 0.517 |
| Phosphate (mg/dL) | 3.9 (3.4-4.5) | 3.8 (3.4-4.4) | 0.160 |
| Total cholesterol (mg/dL) | 172 (143-203) | 165 (143-190) | 0.057 |
| LDL (mg/dL) | 102 (77-128) | 95 (78-113) | 0.117 |
| Triglycerides (mg/dL) | 144 (102-208) | 122 (84-176) | <0.001 |
| Fasting glucose (mg/dL) | 106 (98-130) | 109 (97-125) | 0.713 |
| IL-6 (pg/mL) | 2.93 (1.73-4.82) | 3.80 (2.39-7.17) | <0.001 |
| NT-proBNP (ng/L) | 132 (45-474) | 342 (133-829) | <0.001 |

BMI: Body mass index, BP: Blood pressure, CAD: Coronary artery disease, CCB: Calcium channel blockers, CHF: Congestive heart failure, CVD: Cardiovascular disease, DM: Diabetes mellitus, eGFR: Estimated glomerular filtration rate, IL-6: Interleukin-6, LDL: Low-density lipoprotein, NT-proBNP: N-terminal pro-brain natriuretic peptide, RASB: Renin-angiotensin system blocker, UPCR: Urine protein-to-creatinine ratio
as a “marker” for age-related coexisting comorbid conditions. In contrast, in younger patients, low eGFR results more frequently from a disease process affecting the kidney and is a better predictor of more specific renal outcomes [3]. Another possibility is that elderly patients with impaired renal function tend to die from CVD before they have lived long enough to develop ESKD [8]. However, the results of our competing risk analysis did not support the notion that lower risk of ESKD in older patients was due to a greater competing risk of death. Indeed, a recent study has shown that Taiwanese CKD patients are more likely to develop ESKD than to die [9]. Nevertheless, CVD remained the most common cause of morbidity and mortality in patients with CKD and strategies to prevent or reduce CVD risk factors should be implemented in all patients with CKD irrespective of age.

The substantial heterogeneity in ESKD outcomes between younger and older patients with CKD suggests that the uniform stage-based approach advocated in most practice guidelines is probably inadequate [3]. Current criteria for the diagnosis of CKD in adults include abnormalities of kidney structure or function such as increased proteinuria or an eGFR below 60 mL/min per 1.73 m² present for >3 months. However, this threshold does not separate kidney disease from kidney aging. A reasonable approach would be simply to lower the eGFR threshold for defining CKD in elderly people. It is suggested that elderly people with an eGFR of 45–60 mL/min/1.73 m² and no other evidence of kidney damage might not be labeled as having CKD [10]. Using an age-specific threshold for the diagnosis of CKD may help reduce not only inappropriate care but also its associated adverse effects and costs for healthy older individuals [11].

The strengths of this study include extensive adjustments for baseline characteristics associated with CKD progression in a prospective cohort with long-term follow-up. Moreover, almost all CKD patients who had indications for dialysis started on dialysis in our study. The ascertainment of incident ESKD, the primary outcome measure, was thus unbiased because the onset of ESKD is essentially a treatment decision.

| Table 2: Association of age <65 or ≥65 years and risk of end-stage kidney disease or composite outcome |
|---------------------------------------------------------------|
| Age <65 years   | Age ≥65 years   | P     |
|                  | Cox model, HR (95% CI) |       |
| ESKD             |                  |       |
| Model 1          | 1 (reference)    | 0.73 (0.52-1.03) | 0.070 |
| Model 2          | 1 (reference)    | 0.72 (0.50-1.02) | 0.060 |
| Model 3          | 1 (reference)    | 0.66 (0.45-0.96) | 0.028 |
| Composite outcome of ESKD or death |    |       |
| Model 1          | 1 (reference)    | 1.10 (0.81-1.50) | 0.530 |
| Model 2          | 1 (reference)    | 1.04 (0.76-1.43) | 0.803 |
| Model 3          | 1 (reference)    | 0.94 (0.67-1.32) | 0.723 |

Competing-risk model, sHR (95% CI)

|    | Model 1          | 1 (reference)    | 0.73 (0.49-1.09) | 0.120 |
|    | Model 2          | 1 (reference)    | 0.72 (0.51-1.01) | 0.057 |
|    | Model 3          | 1 (reference)    | 0.65 (0.45-0.95) | 0.026 |

*Adjusted for eGFR, and UPCR, *AAdjusted for covariates in Model 1, sex, smoking history, diabetes, and CVD, *BAdjusted for covariates in Model 2, use of RASB, systolic BP, BMI, hemoglobin, phosphate, IL-6 and NT-proBNP. CI: Confidence interval, ESKD: End-stage kidney disease, HR: Hazard ratio; sHR: Subdistribution HR, eGFR: Estimated glomerular filtration rate, IL-6: Interleukin-6, NT-proBNP: N-terminal pro-brain natriuretic peptide, RASB: Renin-angiotensin system blocker, UPCR: Urine protein-to-creatinine ratio, CVD: Cardiovascular disease, BP: Blood pressure, BMI: Body mass index

Figure 1: Association between aging and incident ESKD in different clinical subgroups. BMI: Body mass index, CI: Confidence interval, CVD: Cardiovascular disease, DM: Diabetes mellitus, HR: Hazard ratio, RASB: Renin-angiotensin system blocker, UPCR: Urine protein-to-creatinine ratio.
However, there are a number of limitations to be considered in interpreting our results. First, as the observational nature of this study, we cannot establish the causality of the relationship between age and clinical outcomes. Second, important risk factors for CKD progression such as dietary protein intake and physical activity were not assessed at the baseline. Third, the MDRD equation has not been validated in the elderly, and there is particular concern that eGFR in the elderly may vary by changes in muscle mass. Finally, no adjustments were made for the multiplicity of exploratory outcomes.

**Conclusion**

In Taiwanese patients with stages 3–5 CKD, the prognostic implications of eGFR for ESKD varied greatly depending on the age of the patient. The relative risk of ESKD is much lower for an elderly patient than for a young patient with the equivalent level of kidney function. Although less likely to develop ESKD than their younger counterparts with CKD, older patients comprise a large and growing population of all new cases of ESKD in Taiwan [12]. Therefore, better prognostic tools with which to identify the small percentage but a large and growing number of older individuals who will progress to ESKD are critically needed. Future research should focus on identifying risk factors at each age and on developing strategies to best treat CKD across the full age spectrum.

**Financial support and sponsorship**

This project was supported by grants from Research Projects MOST 105-2314-B-303-014-MY3, MOST 107-2314-B-303-021, MOST 108-2314-B-303-002-MY3, and MOST 108-2314-B-303-004-MY3, the Ministry of Science and Technology, Taiwan; and Research Projects TCRD-TPE-106-RT-5, TCRD-TPE-108-15, TCRD-TPE-108-19, TCMF-EP 108-06, and TCAS-108-02, Taipei Tzu Chi Hospital, Taiwan.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: A prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008;371:2173-82.
2. National Health Research Institutes Annual Report on Kidney Disease in Taiwan. Available from: http://w3.nhri.org.tw/nhri_org/rl/lib/NewWeb/nhri/ebook/39000400105446(21). [Last accessed on 12 April 20].
3. O’Hare AM, Choi AJ, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 2007;18:2758-65.
4. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
5. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
6. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011;80:93-104.
7. Van Pottelbergh G, Bartholomeeusen S, Buntinx F, Degryse J. The evolution of renal function and the incidence of end-stage renal disease in patients aged ≥50 years. Nephrol Dial Transplant 2012;27:2297-303.
8. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
9. Chiu YL, Chien KL, Lin SL, Chen YM, Tsai TJ, Wu KD. Outcomes of stage 3-5 chronic kidney disease before end-stage renal disease at a single center in Taiwan. Nephron Clin Pract 2008;109:e109-18.
10. Ellam T, Twohig H, Khwaja A. Chronic kidney disease in elderly people: Disease or disease label? BMJ 2016;352:h6559.
11. Delanaye P, Jager KJ, Bökenkamp A, Christensson A, Dubourg L, Eriksen BO, et al. CKD: A call for an age-adapted definition. J Am Soc Nephrol 2019;30:1785-805.
12. Yang WC, Hwang SJ, Taiwan Society of Nephrology. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: The impact of national health insurance. Nephrol Dial Transplant 2008;23:3977-82.